Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Collagens in primary frozen shoulder: expression of collagen mRNA isoforms in the different phases of the disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The rheumatoid arthritis gene expression signature among women who improve or worsen during pregnancy - a pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Rebekka Lund Hansen
  • Tanja Schoedt Jørgensen
  • Lene Dreyer
  • Merete L Hetland
  • Bente Glintborg
  • Johan Askling
  • Daniela Di Giuseppe
  • Lennart T H Jacobsson
  • Johan K Wallman
  • Dan Nordstrom
  • Kalle Aaltonen
  • Eirik K Kristianslund
  • Tore K Kvien
  • Sella A Provan
  • Bjorn Gudbjornsson
  • Thorvadur J Love
  • L E Kristensen
View graph of relations

OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries.

METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment.

RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association.

CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume60
Issue number1
Pages (from-to)140-146
Number of pages7
ISSN1462-0324
DOIs
Publication statusPublished - 1 Jan 2021

    Research areas

  • bDMARDs, international collaborations, prescription patterns, psoriatic arthritis, secular trends of inflammatory hallmarks

ID: 61799855